Peter Kolchinsky portfolio, Q3 2024

RA Capital Management · 13F for the quarter ending Sep 30, 2024

For Q3 2024, RA Capital Management reported $8.7B across 81 US-listed positions, led by ASND (16.7%), PCVX (11.4%) and JANX (4.8%). Compared with its filing for Q2 2024, Peter Kolchinsky opened 9 new positions, added to 9, reduced 14 and sold out of 6; 49 positions did not change.

The largest purchase was a new position in BCAX ($177.2M); the largest sale, the sale of the whole position in Longboard Pharmaceuticals ($88.9M).

Reported value
$8.7B
Positions
81
In the top 10
55%
Filed
Nov 14
2024

Key facts

13F portfolio value
$8.7BQ3 2024
Positions
81
Largest holding
ASND 16.7%
New positions
9
Sold out
6
Filed
Nov 14, 2024

Holdings as of (Q3 2024), filed with the SEC on . Changes are measured against the filing for Jun 30, 2024. Every tracked investor's Q3 2024 13F.

Bought and sold in Q3 2024

Peter Kolchinsky: buys and sells in Q3 2024
StockMoveSharesSizeOf portfolio
Bicara Therapeutics IncBCAX▲ New+6.96M$177.2M2.04%
Artiva Biotherapeutics IncARTV▲ New+9.85M$152.2M1.76%
Longboard Pharmaceuticalsno ticker on file
▼ Sold out−3.29M$88.9M1.03%
Verona Pharma Plcno ticker on file
▼ Reduced 34%−2.62M$75.5M0.87%
Geron CorpGERN▼ Reduced 30%−13.92M$63.2M0.73%
Ascendis Pharma A/SASND▼ Reduced 3.9%−397.97K$59.4M0.69%
Vaxcyte IncPCVX▲ Added 5.9%+485.44K$55.5M0.64%
UroGen Pharma LtdURGN▼ Sold out−3.08M$51.7M0.60%
Bioage Labs IncBIOA▲ New+2.21M$46M0.53%
IDEAYA Biosciences IncIDYA▲ New+1.35M$42.7M0.49%
Avidity Biosciences Incno ticker on file
▲ Added 17%+900K$41.3M0.48%
MBX Biosciences IncMBX▲ New+1.51M$39.3M0.45%
Biogen IncBIIB▲ Added 21%+202.32K$39.2M0.45%
Praxis Precision MedicinesPRAX▼ Reduced 38%−473.64K$27.3M0.31%
Enliven Therapeutics IncELVN▼ Reduced 50%−1.06M$27.1M0.31%
Arcellx Incno ticker on file
▲ Added 15%+247.47K$20.7M0.24%
Nurix Therapeutics IncNRIX▼ Sold out−650K$13.6M0.16%
Cybin Incno ticker on file
▼ Sold out−44M$11.9M0.14%
Dyne Therapeutics IncDYN▲ Added 5.5%+331.94K$11.9M0.14%
Xencor IncXNCR▲ New+575K$11.6M0.13%
RxSight IncRXST▲ Added 6.0%+222K$11M0.13%
Third Harmonic Bio Incno ticker on file
▼ Reduced 37%−752.23K$10.2M0.12%
Avalo Therapeutics IncAVTX▲ New+967K$9.2M0.11%
Macrogenics IncMGNX▼ Sold out−2.08M$8.8M0.10%
Regulus Therapeutics Incno ticker on file
▼ Reduced 88%−5.48M$8.6M0.10%
Cidara Therapeutics Incno ticker on file
▲ New+703.08K$7.6M0.09%
Nuvalent Incno ticker on file
▲ Added 47%+56.49K$5.8M0.07%
Fulcrum Therapeutics IncFULC▼ Reduced 12%−1.38M$4.9M0.06%
AN2 Therapeutics IncANTX▼ Reduced 64%−3.55M$3.8M0.04%
Adagio Medical Holdings IncADGM▲ New+1.33M$3.4M0.04%
Iteos Therapeutics Incno ticker on file
▼ Reduced 9.5%−332.55K$3.4M0.04%
Unicycive Therapeutics IncUNCY▼ Sold out−2.63M$1.3M0.02%
Tenaya Therapeutics IncTNYA▼ Reduced 8.4%−639.76K$1.2M0.01%
Lexeo Therapeutics IncLXEO▼ Reduced 19%−126.16K$1.1M0.01%
Astria Therapeutics Incno ticker on file
▲ Added 1.2%+61.46K$676.6K0.01%
GH Research PLCGHRS▲ Added 1.3%+85K$568.6K0.01%
Metagenomi IncMGX▼ Reduced 12%−172.51K$374.3K0.00%
Alto Neuroscience IncANRO▼ Reduced 0.5%−10.4K$119K0.00%

Holdings at the quarter's end

Peter Kolchinsky holdings, Q3 2024
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q2 2024
1Ascendis Pharma A/SASND · SPONSORED ADRHealth Care16.7%$1.4B9.71M$149.312+ qtrs▼ Reduced 3.9%
2Vaxcyte IncPCVXHealth Care11.4%$992.9M8.69M$114.272+ qtrs▲ Added 5.9%
3Janux Therapeutics IncJANX—4.80%$416.4M9.17M$45.432+ qtrsNo change
4Legend Biotech CorpLEGN · SHHealth Care4.22%$365.8M7.51M$48.732+ qtrsNo change
5Rhythm Pharmaceuticals IncRYTMHealth Care3.68%$318.8M6.08M$52.392+ qtrsNo change
6
Avidity Biosciences Incno ticker on file · SH
—3.34%$289.4M6.3M$45.932+ qtrs▲ Added 17%
7Tyra Biosciences IncTYRA—2.82%$244.9M10.42M$23.512+ qtrsNo change
8Evolent Health IncEVH · SH—2.78%$240.8M8.51M$28.282+ qtrsNo change
9Edgewise Therapeutics IncEWTXHealth Care2.74%$237.8M8.91M$26.692+ qtrsNo change
10Biogen IncBIIB · SHHealth Care2.65%$229.6M1.18M$193.842+ qtrs▲ Added 21%
11Dyne Therapeutics IncDYN · SH—2.64%$229.2M6.38M$35.922+ qtrs▲ Added 5.5%
12RxSight IncRXST · SH—2.23%$193.6M3.92M$49.432+ qtrs▲ Added 6.0%
13Bicara Therapeutics IncBCAX—2.04%$177.2M6.96M$25.471 qtrNew
14Climb Bio IncCLYM—1.84%$159.9M31.42M$5.092+ qtrsNo change
15Ars Pharmaceuticals IncSPRY—1.82%$157.5M10.86M$14.502+ qtrsNo change
16
Arcellx Incno ticker on file · SH
—1.78%$154.6M1.85M$83.512+ qtrs▲ Added 15%
17Artiva Biotherapeutics IncARTV—1.76%$152.2M9.85M$15.451 qtrNew
18Wave Life Sciences LtdWVE—1.72%$149.3M18.2M$8.202+ qtrsNo change
19Geron CorpGERN—1.69%$146.6M32.29M$4.542+ qtrs▼ Reduced 30%
20
Verona Pharma Plcno ticker on file · SH
—1.66%$144.1M5.01M$28.772+ qtrs▼ Reduced 34%
21Newamsterdam Pharma CompanyNAMS—1.54%$133.9M8.06M$16.602+ qtrsNo change
22
Apogee Therapeutics Incno ticker on file · SH
—1.33%$115.2M1.96M$58.742+ qtrsNo change
23
Day One Biopharmaceuticalsno ticker on file · SH
—1.26%$109.7M7.87M$13.932+ qtrsNo change
24
89BIO Incno ticker on file · SH
—1.21%$104.9M14.18M$7.402+ qtrsNo change
25Recursion Pharmaceuticals IncRXRX · SH—1.17%$101.4M15.38M$6.592+ qtrsNo change
26Lenz Therapeutics IncLENZ—1.14%$99.2M4.18M$23.742+ qtrsNo change
27Pepgen IncPEPG—1.05%$91.4M10.69M$8.552+ qtrsNo change
28Axsome Therapeutics IncAXSM · SHHealth Care1.04%$89.9M1M$89.872+ qtrsNo change
29Structure Therapeutics IncGPCR · SH—0.96%$83.2M1.9M$43.892+ qtrsNo change
30
Tourmaline Bio Incno ticker on file · SH
—0.75%$65.3M2.54M$25.712+ qtrsNo change
31Dianthus Therapeutics IncDNTHHealth Care0.74%$63.9M2.33M$27.382+ qtrsNo change
32Mineralys Therapeutics IncMLYS—0.68%$58.7M4.85M$12.112+ qtrsNo change
33Acrivon Therapeutics IncACRV—0.67%$58.4M8.34M$7.002+ qtrsNo change
34
Astria Therapeutics Incno ticker on file · SH
—0.65%$56.2M5.11M$11.012+ qtrs▲ Added 1.2%
354D Molecular TherapeuticsFDMT—0.64%$55.1M5.1M$10.812+ qtrsNo change
36CG Oncology IncCGON · SHHealth Care0.61%$52.7M1.4M$37.732+ qtrsNo change
37Bicycle Therapeutics PlcBCYC · SH—0.59%$51M2.25M$22.632+ qtrsNo change
38Nkarta IncNKTX—0.56%$48.8M10.81M$4.522+ qtrsNo change
39Bioage Labs IncBIOA—0.53%$46M2.21M$20.801 qtrNew
40GH Research PLCGHRS—0.52%$44.7M6.69M$6.692+ qtrs▲ Added 1.3%
41Praxis Precision MedicinesPRAXHealth Care0.51%$43.8M761.96K$57.542+ qtrs▼ Reduced 38%
42IDEAYA Biosciences IncIDYA · SH—0.49%$42.7M1.35M$31.681 qtrNew
43Larimar Therapeutics IncLRMR · SH—0.46%$39.6M6.05M$6.552+ qtrsNo change
44MBX Biosciences IncMBX · SH—0.45%$39.3M1.51M$25.981 qtrNew
45Acumen Pharmaceuticals IncABOS—0.43%$37M14.93M$2.482+ qtrsNo change
46Fulcrum Therapeutics IncFULC—0.42%$36.5M10.23M$3.572+ qtrs▼ Reduced 12%
47
Iteos Therapeutics Incno ticker on file · SH
—0.38%$32.5M3.18M$10.212+ qtrs▼ Reduced 9.5%
48Solid Biosciences IncSLDB—0.35%$30.2M4.33M$6.972+ qtrsNo change
49C4 Therapeutics IncCCCC—0.32%$27.8M4.88M$5.702+ qtrsNo change
50Enliven Therapeutics IncELVN · SH—0.31%$27.1M1.06M$25.542+ qtrs▼ Reduced 50%
51Alto Neuroscience IncANRO · SH—0.27%$23.7M2.08M$11.442+ qtrs▼ Reduced 0.5%
52Sera Prognostics IncSERA · SH—0.27%$23.7M3.03M$7.802+ qtrsNo change
53Taysha Gene Therapies IncTSHA—0.25%$21.9M10.87M$2.012+ qtrsNo change
54Immatics N.V.IMTX · SH—0.23%$20M1.75M$11.412+ qtrsNo change
55
Aerovate Therapeutics Incno ticker on file · SH
—0.22%$19.2M9.19M$2.092+ qtrsNo change
56
Nuvalent Incno ticker on file
—0.21%$18M176.28K$102.302+ qtrs▲ Added 47%
57
Third Harmonic Bio Incno ticker on file · SH
—0.20%$17.4M1.28M$13.552+ qtrs▼ Reduced 37%
58Vor Biopharma IncVOR · SH—0.18%$15.9M22.75M$0.70002+ qtrsNo change
59Insmed IncINSM · SHHealth Care0.17%$14.6M200K$73.002+ qtrsNo change
60Pliant Therapeutics IncPLRX · SH—0.17%$14.4M1.28M$11.212+ qtrsNo change
61Tenaya Therapeutics IncTNYA · SH—0.16%$13.5M6.98M$1.932+ qtrs▼ Reduced 8.4%
62Zura Bio LtdZURA · SH—0.15%$13.1M3.22M$4.062+ qtrsNo change
63Werewolf Therapeutics IncHOWL—0.15%$13M6.14M$2.122+ qtrsNo change
64Cervomed IncCRVO · SH—0.14%$11.9M817.12K$14.602+ qtrsNo change
65Xencor IncXNCR—0.13%$11.6M575K$20.111 qtrNew
66Adicet Bio IncACET · SH—0.13%$10.9M7.54M$1.442+ qtrsNo change
67Arvinas IncARVN · SH—0.12%$10.4M421.35K$24.632+ qtrsNo change
68Avalo Therapeutics IncAVTX—0.11%$9.2M967K$9.501 qtrNew
69
Chimerix Incno ticker on file · SH
—0.09%$8.2M8.8M$0.93002+ qtrsNo change
70Boundless Bio IncBOLD · SH—0.09%$7.6M2.18M$3.472+ qtrsNo change
71
Cidara Therapeutics Incno ticker on file · SH
—0.09%$7.6M703.08K$10.751 qtrNew
72
Perceptive Cap Solutionsno ticker on file
—0.09%$7.5M750K$10.022+ qtrsNo change
73Lexeo Therapeutics IncLXEO—0.06%$4.9M546.55K$9.042+ qtrs▼ Reduced 19%
74Protara Therapeutics IncTARA · SH—0.04%$3.5M1.9M$1.832+ qtrsNo change
75Adagio Medical Holdings IncADGM · SH—0.04%$3.4M1.33M$2.581 qtrNew
76Surrozen IncSRZN · SH—0.04%$3.4M282.58K$11.982+ qtrsNo change
77Metagenomi IncMGX · SH—0.03%$2.8M1.31M$2.172+ qtrs▼ Reduced 12%
78
Newamsterdam Pharma Co NV-27no ticker on file · WTS
—0.03%$2.3M333.33K$7.002+ qtrsNo change
79AN2 Therapeutics IncANTX · SH—0.03%$2.1M2M$1.072+ qtrs▼ Reduced 64%
80
Regulus Therapeutics Incno ticker on file · SH
—0.01%$1.2M766.83K$1.572+ qtrs▼ Reduced 88%
81
Scilex Holding Cono ticker on file · SH
—0.00%$241.5K261.18K$0.92462+ qtrsNo change

By sector

Peter Kolchinsky portfolio by sector, Q3 2024
SectorShare of portfolioValuePositions
Health Care44.5%$3.9B11
No sector on file55.5%$4.8B70

Questions and answers

What did Peter Kolchinsky own in Q3 2024?

RA Capital Management's 13F for Q3 2024 lists 81 positions worth $8.7B. The largest: ASND (16.7%), PCVX (11.4%), JANX (4.8%), LEGN (4.2%), RYTM (3.7%).

What did Peter Kolchinsky buy in Q3 2024?

The largest purchases, by the shares bought at the quarter-end price the filing implies: BCAX (new, $177.2M), ARTV (new, $152.2M), PCVX (added, $55.5M), BIOA (new, $46M), IDYA (new, $42.7M), Avidity Biosciences Inc (added, $41.3M).

What did Peter Kolchinsky sell in Q3 2024?

The largest sales: Longboard Pharmaceuticals (sold out, $88.9M), Verona Pharma Plc (reduced, $75.5M), GERN (reduced, $63.2M), ASND (reduced, $59.4M), URGN (sold out, $51.7M), PRAX (reduced, $27.3M).

When was this filing made?

RA Capital Management filed its 13F for the quarter ending Sep 30, 2024 on Nov 14, 2024. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Peter Kolchinsky portfolio, Q3 2024: RA Capital Management 13F holdings”, data as of 14 November 2024. https://funkfolio.com/gurus/peter-kolchinsky/2024-q3

Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Sep 30, 2024.

Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Sep 30, 2024, filed Nov 14, 2024. Changes compare share counts with the filing for Jun 30, 2024; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $8.7B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 2 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.